• Je něco špatně v tomto záznamu ?

Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical Experience

D. Šaňák, S. Jakubíček, D. Černík, R. Herzig, Z. Kunáš, R. Mikulík, S. Ostrý, M. Reif, V. Rohan, A. Tomek, T. Veverka,

. 2018 ; 27 (9) : 2479-2483. [pub] 20180525

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19000697

BACKGROUND: Intravenous thrombolysis (IVT) is contraindicated in patients with acute ischemic stroke (AIS) using oral anticoagulants. A specific human monoclonal antibody was introduced to reverse immediately the anticoagulation effect of the direct inhibitor of thrombin, dabigatran. Until now, mostly individual cases presenting with successful IVT after a reversal of dabigatran anticoagulation in patients with AIS were published. Thus, we aimed to report real-world data from clinical practice. METHODS: Patients with AIS on dabigatran treated with IVT after antidote reversal were enrolled in the retrospective nationwide study. Neurological deficit was scored using the National Institutes of Health Stroke Scale (NIHSS) and 90-day clinical outcome using modified Rankin scale (mRS) with a score 0-2 for a good outcome. Intracerebral hemorrhage (ICH) was defined as a presence of any sign of bleeding on control imaging after IVT, and symptomatic intracerebral hemorrhage (SICH) was assessed according to the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) criteria. RESULTS: In total, 13 patients (7 men, mean age 70.0 ± 9.1 years) with a median NIHSS admission score of 7 points were analyzed. Of these patients, 61.5% used 2 × 150 mg of dabigatran daily. Antidote was administrated 427 ± 235 minutes after the last intake of dabigatran, with a mean activated prothrombin time of 38.1 ± 27.8 seconds and a mean thrombin time of 72.2 ± 56.1 seconds. Of the 13 patients, 2 had ICH and 1 had SICH, and no other bleeding complications were observed after IVT. Of the total number of patients, 76.9% had a good 3-month clinical outcome and 3 patients (23.1%) died. Recurrent ischemic stroke occurred in 2 patients (15.4%). CONCLUSION: The data presented in the study support the safety and efficacy of IVT after the reversal of the anticoagulation effect of dabigatran with antidote in a real-world clinical practice.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19000697
003      
CZ-PrNML
005      
20190218174110.0
007      
ta
008      
190107s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jstrokecerebrovasdis.2018.05.004 $2 doi
035    __
$a (PubMed)29807757
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Šaňák, Daniel $u Comprehensive Stroke Center, Department of Neurology, Palacký University Medical School and Hospital, Olomouc, Czech Republic. Electronic address: daniel.sanak@centrum.cz.
245    10
$a Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical Experience / $c D. Šaňák, S. Jakubíček, D. Černík, R. Herzig, Z. Kunáš, R. Mikulík, S. Ostrý, M. Reif, V. Rohan, A. Tomek, T. Veverka,
520    9_
$a BACKGROUND: Intravenous thrombolysis (IVT) is contraindicated in patients with acute ischemic stroke (AIS) using oral anticoagulants. A specific human monoclonal antibody was introduced to reverse immediately the anticoagulation effect of the direct inhibitor of thrombin, dabigatran. Until now, mostly individual cases presenting with successful IVT after a reversal of dabigatran anticoagulation in patients with AIS were published. Thus, we aimed to report real-world data from clinical practice. METHODS: Patients with AIS on dabigatran treated with IVT after antidote reversal were enrolled in the retrospective nationwide study. Neurological deficit was scored using the National Institutes of Health Stroke Scale (NIHSS) and 90-day clinical outcome using modified Rankin scale (mRS) with a score 0-2 for a good outcome. Intracerebral hemorrhage (ICH) was defined as a presence of any sign of bleeding on control imaging after IVT, and symptomatic intracerebral hemorrhage (SICH) was assessed according to the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) criteria. RESULTS: In total, 13 patients (7 men, mean age 70.0 ± 9.1 years) with a median NIHSS admission score of 7 points were analyzed. Of these patients, 61.5% used 2 × 150 mg of dabigatran daily. Antidote was administrated 427 ± 235 minutes after the last intake of dabigatran, with a mean activated prothrombin time of 38.1 ± 27.8 seconds and a mean thrombin time of 72.2 ± 56.1 seconds. Of the 13 patients, 2 had ICH and 1 had SICH, and no other bleeding complications were observed after IVT. Of the total number of patients, 76.9% had a good 3-month clinical outcome and 3 patients (23.1%) died. Recurrent ischemic stroke occurred in 2 patients (15.4%). CONCLUSION: The data presented in the study support the safety and efficacy of IVT after the reversal of the anticoagulation effect of dabigatran with antidote in a real-world clinical practice.
650    _2
$a intravenózní podání $7 D061605
650    _2
$a senioři $7 D000368
650    _2
$a humanizované monoklonální protilátky $x škodlivé účinky $x terapeutické užití $7 D061067
650    _2
$a antikoagulancia $x škodlivé účinky $x terapeutické užití $7 D000925
650    _2
$a antidota $x škodlivé účinky $x terapeutické užití $7 D000931
650    _2
$a ischemie mozku $x farmakoterapie $x mortalita $7 D002545
650    _2
$a cerebrální krvácení $x etiologie $7 D002543
650    _2
$a dabigatran $x škodlivé účinky $x terapeutické užití $7 D000069604
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibrinolytika $x aplikace a dávkování $x škodlivé účinky $7 D005343
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a rekombinantní proteiny $x aplikace a dávkování $x škodlivé účinky $7 D011994
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a cévní mozková příhoda $x farmakoterapie $x mortalita $7 D020521
650    12
$a trombolytická terapie $x škodlivé účinky $7 D015912
650    _2
$a tkáňový aktivátor plazminogenu $x aplikace a dávkování $x škodlivé účinky $7 D010959
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jakubíček, Stanislava $u Department of Neurology, Masaryk University Faculty of Medicine and St. Anne's University Hospital, Brno, Czech Republic.
700    1_
$a Černík, David $7 xx0232584 $u Department of Neurology, Comprehensive Stroke Center, Masaryk Hospital Ústí nad Labem, KZ A.S., Ústí nad Labem, Czech Republic.
700    1_
$a Herzig, Roman $u Department of Neurology, Comprehensive Stroke Center, Charles University Faculty of Medicine and University Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Kunáš, Zdeněk $u Department of Neurology, Comprehensive Stroke Center, Hospital České Budějovice, České Budějovice, Czech Republic.
700    1_
$a Mikulík, Robert $u International Clinical Research Center and Department of Neurology, St. Anne's University Hospital, Brno, Czech Republic.
700    1_
$a Ostrý, Svatopluk $u Department of Neurology, Comprehensive Stroke Center, Hospital České Budějovice, České Budějovice, Czech Republic.
700    1_
$a Reif, Michal $u International Clinical Research Center and Department of Neurology, St. Anne's University Hospital, Brno, Czech Republic.
700    1_
$a Rohan, Vladimír $u Department of Neurology, Faculty of Medicine in Plzen, Comprehensive Stroke Center, Charles University in Prague and Faculty Hospital Plzen, Pilsen, Czech Republic.
700    1_
$a Tomek, Aleš $u Department of Neurology, Comprehensive Stroke Center, Charles University Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Veverka, Tomáš $u Comprehensive Stroke Center, Department of Neurology, Palacký University Medical School and Hospital, Olomouc, Czech Republic.
773    0_
$w MED00167194 $t Journal of stroke and cerebrovascular diseases the official journal of National Stroke Association $x 1532-8511 $g Roč. 27, č. 9 (2018), s. 2479-2483
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29807757 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190218174402 $b ABA008
999    __
$a ok $b bmc $g 1363901 $s 1038820
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 27 $c 9 $d 2479-2483 $e 20180525 $i 1532-8511 $m Journal of stroke and cerebrovascular diseases $n J Stroke Cerebrovasc Dis $x MED00167194
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...